Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test 2026 - Free AOCNP Practice Questions and Study Guide

The management of tumor lysis syndrome (TLS) primarily focuses on preventing and treating the metabolic abnormalities that occur when a large number of tumor cells are killed off rapidly, leading to the release of intracellular contents into the bloodstream. This can result in complications such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.

Fluid hydration is a cornerstone of TLS management as it helps to maintain renal perfusion, dilute serum electrolytes, and facilitate the excretion of metabolic byproducts. Chemotherapy can also contribute indirectly to TLS; while it can induce the syndrome, it is part of the broader management strategy, especially in high-risk cases where proactive measures may be needed. Diuretics can be employed cautiously to help with fluid management and promote the excretion of excess uric acid and electrolytes, although their usage needs to be carefully monitored.

Bone marrow transplant, on the other hand, is not a direct therapeutic strategy for managing TLS. It is typically indicated in cases where a hematological malignancy warrants such a procedure, but it does not address or alleviate the metabolic disturbances associated with TLS. Therefore, it is not considered a typical management approach for this condition. The focus in TLS is on immediate correction of metabolic der